· Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and
ACCORD2_002
  · Data receipt is ongoing and evaluation of efficacy data is underway
  · Exploratory analyses are looking to define subsets of patients with baseline
markers indicative of increased disease severity with the potential for greater
benefit
  · Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study
there was a numerically lower number of deaths up to day 29 in the bemcentinib
arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated
with standard of care alone)